Progyny (PGNY) Expected to Announce Quarterly Earnings on Thursday

Progyny (NASDAQ:PGNY) is expected to release its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Progyny to post earnings of $0.38 per share for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:45 PM ET.

Progyny Stock Performance

Shares of PGNY stock opened at $20.78 on Wednesday. The stock has a 50 day moving average price of $24.26 and a 200 day moving average price of $23.15. Progyny has a 52-week low of $17.98 and a 52-week high of $28.75. The firm has a market capitalization of $1.79 billion, a P/E ratio of 32.98, a P/E/G ratio of 1.35 and a beta of 0.96.

Institutional Trading of Progyny

A number of hedge funds have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd purchased a new position in shares of Progyny in the 4th quarter valued at $25,000. Canada Pension Plan Investment Board bought a new stake in Progyny during the second quarter valued at about $77,000. Quarry LP grew its stake in Progyny by 2,004.1% in the third quarter. Quarry LP now owns 3,598 shares of the company’s stock valued at $77,000 after purchasing an additional 3,427 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in Progyny by 203.5% in the second quarter. Tower Research Capital LLC TRC now owns 7,021 shares of the company’s stock worth $154,000 after purchasing an additional 4,708 shares in the last quarter. Finally, Entropy Technologies LP bought a new position in Progyny in the fourth quarter worth about $203,000. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. BTIG Research reissued a “buy” rating on shares of Progyny in a research note on Wednesday, January 21st. Barclays assumed coverage on shares of Progyny in a report on Monday, December 8th. They set an “overweight” rating and a $29.00 price objective for the company. Canaccord Genuity Group upped their target price on shares of Progyny from $23.00 to $26.00 and gave the stock a “hold” rating in a research note on Monday, November 17th. Citigroup raised shares of Progyny to an “outperform” rating in a research note on Tuesday, January 20th. Finally, Truist Financial raised Progyny from a “hold” rating to a “buy” rating and set a $34.00 price objective on the stock in a research note on Thursday, January 8th. Eight investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $29.80.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.